EA200702216A1 - Композиции в форме наночастиц с контролируемым высвобождением, содержащие циклоспорин - Google Patents
Композиции в форме наночастиц с контролируемым высвобождением, содержащие циклоспоринInfo
- Publication number
- EA200702216A1 EA200702216A1 EA200702216A EA200702216A EA200702216A1 EA 200702216 A1 EA200702216 A1 EA 200702216A1 EA 200702216 A EA200702216 A EA 200702216A EA 200702216 A EA200702216 A EA 200702216A EA 200702216 A1 EA200702216 A1 EA 200702216A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cyclosporin
- nanoparticles
- compositions
- psoriasis
- rheumatoid arthritis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Настоящее изобретение направлено на композицию, содержащую циклоспорин в форме наночастиц, имеющий повышенную биодоступность. Наночастицы циклоспорин композиции имеют эффективный средний размер частиц менее чем приблизительно 2000 нм в диаметре и пригодны для предотвращения и лечения отторжения трансплантированного органа и аутоиммунных заболеваний, таких как псориаз, ревматоидный артрит и других родственных заболеваний. Изобретение также относится к композиции с контролируемым высвобождением, содержащей циклоспорин или циклоспорин в форме наночастиц, которая во время ее применения доставляет препарат в импульсном или бимодальном режиме для предотвращения и лечения отторжения трансплантированного органа и аутоиммунных заболеваний, таких как псориаз, ревматоидный артрит и других родственных заболеваний.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67083605P | 2005-04-12 | 2005-04-12 | |
PCT/US2006/013631 WO2006110802A1 (en) | 2005-04-12 | 2006-04-12 | Nanoparticulate and controlled release compositions comprising cyclosporine |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200702216A1 true EA200702216A1 (ru) | 2008-08-29 |
Family
ID=37087359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200702216A EA200702216A1 (ru) | 2005-04-12 | 2006-04-12 | Композиции в форме наночастиц с контролируемым высвобождением, содержащие циклоспорин |
Country Status (14)
Country | Link |
---|---|
US (2) | US7825087B2 (ru) |
EP (1) | EP1868582A4 (ru) |
JP (1) | JP2008535921A (ru) |
KR (1) | KR20080007580A (ru) |
CN (1) | CN101171000A (ru) |
AU (1) | AU2006235478B2 (ru) |
BR (1) | BRPI0609071A2 (ru) |
CA (1) | CA2603084A1 (ru) |
EA (1) | EA200702216A1 (ru) |
IL (1) | IL186469A0 (ru) |
MX (1) | MX2007012762A (ru) |
NO (1) | NO20075696L (ru) |
WO (1) | WO2006110802A1 (ru) |
ZA (1) | ZA200708260B (ru) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006110802A1 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
US9044391B2 (en) * | 2007-01-10 | 2015-06-02 | Board Of Regents, The University Of Texas System | Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery |
ES2393814T3 (es) | 2007-04-04 | 2012-12-28 | Sigmoid Pharma Limited | Una composición farmacéutica oral |
EP3498367A1 (en) | 2009-02-09 | 2019-06-19 | Cellutech AB | Polymer shells |
EP2396070A4 (en) | 2009-02-12 | 2012-09-19 | Incept Llc | ACTIVE COMPOSITION WITH HYDROGEL PLUGS |
DK2471518T3 (en) | 2009-05-18 | 2017-12-04 | Sigmoid Pharma Ltd | COMPOSITION INCLUDING OIL DROPS |
JP6072539B2 (ja) | 2009-05-27 | 2017-02-01 | アルカーメス ファーマ アイルランド リミテッド | ナノ粒子活性物質組成物におけるフレーク状凝集の軽減 |
IN2012DN00781A (ru) | 2009-08-12 | 2015-06-26 | Sigmoid Pharma Ltd | |
US9012511B2 (en) | 2010-05-19 | 2015-04-21 | Alkermes Pharma Ireland Limited | Nanoparticulate cinacalcet compositions |
GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
EP2659903B1 (en) * | 2010-12-28 | 2016-09-14 | Hanlim Pharmaceutical Co., Ltd. | Nanoemulsion-type ophthalmic composition |
GB201100786D0 (en) * | 2011-01-18 | 2011-03-02 | Ems Sa | Pharmaceutical compositions of immunosuppressants |
US8287903B2 (en) * | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
CA2858161C (en) | 2011-12-05 | 2020-03-10 | Incept, Llc | Medical organogel processes and compositions |
CN104602675B (zh) | 2012-06-21 | 2019-06-28 | 法斯瑞斯公司 | 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法 |
GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
GB201222455D0 (en) * | 2012-12-13 | 2013-01-30 | Perioc Ltd | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease |
GB201304662D0 (en) | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
GB201319792D0 (en) * | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
US20150352176A1 (en) * | 2014-06-06 | 2015-12-10 | Newport Research, Inc. | Oil-free and fat-free aqueous suspensions of cyclosporin |
CN104717963B (zh) * | 2014-09-22 | 2016-12-14 | 江苏大学 | 一种双层包衣的环孢素a缓释微丸制剂及其制备方法 |
EP3881829A1 (en) | 2014-11-07 | 2021-09-22 | Sublimity Therapeutics Limited | Compositions comprising cyclosporin |
US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
CN107921151A (zh) | 2015-05-27 | 2018-04-17 | 匹兹堡大学联邦系统高等教育 | 降低成像后胰腺炎风险的组合物和方法 |
CN108348468A (zh) * | 2015-08-11 | 2018-07-31 | Eyesiu医疗股份有限公司 | 具有生物活性亲脂性化合物的聚乙二醇化脂质纳米粒 |
KR102146704B1 (ko) * | 2018-04-13 | 2020-08-21 | 가천대학교 산학협력단 | 사이클로스포린 A (CsA) 경피 및 피내 약물전달용 마이크로구조체 |
CN110779787B (zh) * | 2019-11-15 | 2022-04-29 | 北京丹大生物技术有限公司 | 一种环孢霉素全血样本的前处理剂及其使用方法 |
TW202408579A (zh) * | 2022-07-20 | 2024-03-01 | 日商旭化成股份有限公司 | 玻尿酸衍生物醫藥品組合物及醫藥品組合物 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
US5639724A (en) | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
US4783484A (en) * | 1984-10-05 | 1988-11-08 | University Of Rochester | Particulate composition and use thereof as antimicrobial agent |
US4825589A (en) * | 1987-03-09 | 1989-05-02 | Straw Jesse H | Hanging plant carrier |
US5756450A (en) * | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
FR2659234B1 (fr) * | 1990-03-12 | 1994-07-01 | Fileco Sa | Composition therapeutique contenant un compose phenol et de la propolis utile contre les virus a capside lipidique, notamment les virus de l'herpes. |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
JPH06511481A (ja) | 1991-07-05 | 1994-12-22 | ユニバーシティ オブ ロチェスター | 気泡を取り込む超微小非凝集多孔質粒子 |
EP0642332B1 (en) | 1992-05-13 | 1997-01-15 | Sandoz Ltd. | Ophthalmic compositions containing a cyclosporin |
NZ248813A (en) * | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
US5349957A (en) * | 1992-12-02 | 1994-09-27 | Sterling Winthrop Inc. | Preparation and magnetic properties of very small magnetite-dextran particles |
US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5340564A (en) * | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5352459A (en) * | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
US5401492A (en) * | 1992-12-17 | 1995-03-28 | Sterling Winthrop, Inc. | Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents |
US5326552A (en) * | 1992-12-17 | 1994-07-05 | Sterling Winthrop Inc. | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants |
US5264610A (en) * | 1993-03-29 | 1993-11-23 | Sterling Winthrop Inc. | Iodinated aromatic propanedioates |
US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5525328A (en) * | 1994-06-24 | 1996-06-11 | Nanosystems L.L.C. | Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging |
US5587143A (en) * | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
RU2158601C2 (ru) | 1994-11-03 | 2000-11-10 | Новартис Аг | Новые лекарственные формы циклоспорина для орального применения с простым составом и высокой биодоступностью и способ их получения |
US5466440A (en) * | 1994-12-30 | 1995-11-14 | Eastman Kodak Company | Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays |
US5585108A (en) * | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5628981A (en) | 1994-12-30 | 1997-05-13 | Nano Systems L.L.C. | Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents |
US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5560932A (en) * | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5569448A (en) * | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5560931A (en) * | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5571536A (en) * | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5593657A (en) * | 1995-02-09 | 1997-01-14 | Nanosystems L.L.C. | Barium salt formulations stabilized by non-ionic and anionic stabilizers |
US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5622938A (en) * | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
US5500204A (en) * | 1995-02-10 | 1996-03-19 | Eastman Kodak Company | Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging |
US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5573783A (en) * | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5543133A (en) * | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
US5580579A (en) * | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
DE69633222T2 (de) | 1995-02-24 | 2005-09-08 | Elan Pharma International Ltd. | Nanopartikel-dispersionen enthaltende aerosole |
US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
US5565188A (en) * | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US5472683A (en) * | 1995-03-09 | 1995-12-05 | Eastman Kodak Company | Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging |
US5643552A (en) | 1995-03-09 | 1997-07-01 | Nanosystems L.L.C. | Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging |
US5573749A (en) * | 1995-03-09 | 1996-11-12 | Nano Systems L.L.C. | Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging |
GB9618952D0 (en) | 1996-09-11 | 1996-10-23 | Sandoz Ltd | Process |
US5521218A (en) * | 1995-05-15 | 1996-05-28 | Nanosystems L.L.C. | Nanoparticulate iodipamide derivatives for use as x-ray contrast agents |
US5573750A (en) * | 1995-05-22 | 1996-11-12 | Nanosystems L.L.C. | Diagnostic imaging x-ray contrast agents |
US5962019A (en) | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US5834017A (en) | 1995-08-25 | 1998-11-10 | Sangstat Medical Corporation | Oral cyclopsporin formulations |
US5827822A (en) | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
US5766629A (en) | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
NZ333657A (en) | 1996-07-30 | 2000-05-26 | Novartis Ag | A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin |
SK285019B6 (sk) | 1997-01-30 | 2006-04-06 | Novartis Ag | Tvrdá želatínová tobolka |
US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
IT1289938B1 (it) | 1997-02-20 | 1998-10-19 | Angelini Ricerche Spa | Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e |
US6358425B1 (en) | 1998-03-09 | 2002-03-19 | Joseph A. King | Pool cleaning and sanitizing apparatus |
US6153225A (en) | 1998-08-13 | 2000-11-28 | Elan Pharma International Limited | Injectable formulations of nanoparticulate naproxen |
US6165506A (en) | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
CA2653839A1 (en) * | 1998-11-02 | 2000-05-11 | John G. Devane | Multiparticulate modified release composition |
US6375986B1 (en) | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US6270806B1 (en) | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
US6267989B1 (en) | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
GB9912476D0 (en) | 1999-05-28 | 1999-07-28 | Novartis Ag | Organic compounds |
JP4156807B2 (ja) | 1999-06-01 | 2008-09-24 | エラン ファーマ インターナショナル,リミティド | 小型ミル及びその方法 |
US6273339B1 (en) * | 1999-08-30 | 2001-08-14 | Micron Technology, Inc. | Tamper resistant smart card and method of protecting data in a smart card |
US6656504B1 (en) * | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
IL148685A0 (en) * | 1999-09-21 | 2002-09-12 | Rtp Pharma Inc | Surface modified particulate compositions of biologically active substances |
US6583183B2 (en) * | 1999-09-23 | 2003-06-24 | Pharmacia Corporation | Substituted n-phenyl-n-fused-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
CA2492488A1 (en) * | 2002-07-16 | 2004-01-22 | Elan Pharma International, Ltd. | Liquid dosage compositions of stable nanoparticulate active agents |
WO2004043440A1 (en) * | 2002-11-12 | 2004-05-27 | Elan Pharma International Ltd. | Fast-disintegrating solid dosage forms being not friable and comprising pullulan |
JP2006528985A (ja) * | 2003-05-19 | 2006-12-28 | バクスター・インターナショナル・インコーポレイテッド | 1つ以上の界面改変剤でコーティングされた、抗癲癇剤または免疫抑制剤を含有する固体粒子 |
WO2006110802A1 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
-
2006
- 2006-04-12 WO PCT/US2006/013631 patent/WO2006110802A1/en active Application Filing
- 2006-04-12 CA CA002603084A patent/CA2603084A1/en not_active Abandoned
- 2006-04-12 JP JP2008506629A patent/JP2008535921A/ja not_active Withdrawn
- 2006-04-12 AU AU2006235478A patent/AU2006235478B2/en not_active Expired - Fee Related
- 2006-04-12 KR KR1020077026124A patent/KR20080007580A/ko not_active Application Discontinuation
- 2006-04-12 US US11/568,692 patent/US7825087B2/en not_active Expired - Fee Related
- 2006-04-12 EA EA200702216A patent/EA200702216A1/ru unknown
- 2006-04-12 CN CNA2006800156761A patent/CN101171000A/zh active Pending
- 2006-04-12 EP EP06749866A patent/EP1868582A4/en not_active Withdrawn
- 2006-04-12 BR BRPI0609071-0A patent/BRPI0609071A2/pt not_active IP Right Cessation
- 2006-04-12 MX MX2007012762A patent/MX2007012762A/es active IP Right Grant
-
2007
- 2007-09-27 ZA ZA200708260A patent/ZA200708260B/xx unknown
- 2007-10-07 IL IL186469A patent/IL186469A0/en unknown
- 2007-11-07 NO NO20075696A patent/NO20075696L/no not_active Application Discontinuation
-
2010
- 2010-09-23 US US12/888,530 patent/US20110064800A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2006235478B2 (en) | 2011-07-21 |
NO20075696L (no) | 2008-01-03 |
AU2006235478A1 (en) | 2006-10-19 |
BRPI0609071A2 (pt) | 2010-11-16 |
WO2006110802A1 (en) | 2006-10-19 |
MX2007012762A (es) | 2008-01-14 |
CA2603084A1 (en) | 2006-10-19 |
US7825087B2 (en) | 2010-11-02 |
KR20080007580A (ko) | 2008-01-22 |
ZA200708260B (en) | 2010-05-26 |
JP2008535921A (ja) | 2008-09-04 |
US20110064800A1 (en) | 2011-03-17 |
EP1868582A4 (en) | 2011-06-22 |
EP1868582A1 (en) | 2007-12-26 |
US20080124389A1 (en) | 2008-05-29 |
IL186469A0 (en) | 2008-01-20 |
CN101171000A (zh) | 2008-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200702216A1 (ru) | Композиции в форме наночастиц с контролируемым высвобождением, содержащие циклоспорин | |
Wu et al. | ZnL2-BPs integrated bone scaffold under sequential photothermal mediation: a win–win strategy delivering antibacterial therapy and fostering osteogenesis thereafter | |
EA200701442A1 (ru) | Композиции наночастиц кандесартана | |
EA200702444A1 (ru) | Композиции с наночастицами клопидогреля | |
EA201170040A1 (ru) | Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и способы их получения и применения | |
MD20070267A (en) | Gastroresistant pharmaceutical formulation containing rifaximin | |
NO20073289L (no) | Nanopartikkelsammensetninger med kontrollert frigjoring som omfatter cephalosporin | |
Yang et al. | Dual-purpose magnesium-incorporated titanium nanotubes for combating bacterial infection and ameliorating osteolysis to realize better osseointegration | |
EA201171195A1 (ru) | Конъюгаты, частицы, композиции "полимер-агент" и способы их применения | |
EA201290498A1 (ru) | Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения | |
WO2007061677A3 (en) | Spirolactam aryl cgrp receptor antagonists | |
RU2017138372A (ru) | Магниевый сплав, способ его производства и использования | |
WO2007005249A3 (en) | Nanoparticles and dendritic-polymer-based hydrogels comprising them | |
WO2006118954A3 (en) | Inhibition of reactive oxygen species and protection of mammalian cells | |
EA201290497A1 (ru) | Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых | |
RS20080167A (en) | Novel improved compositions for cancer therapy | |
TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
EP4242655A3 (en) | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway | |
WO2006044497A3 (en) | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease | |
WO2007061692A3 (en) | Spirolactam tricyclic cgrp receptor antagonists | |
PE20091265A1 (es) | Nanoparticulas que contienen pioglitazona | |
ATE422880T1 (de) | Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen | |
WO2008109347A3 (en) | Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles | |
WO2007061694A3 (en) | Spirohydantoin tricyclic cgrp receptor antagonists | |
ATE419236T1 (de) | 3,6-disubstituierte azabicyclo-3.1.0 hexan- derivate als muscarinische rezeptorantagonisten |